Braintree Labs Hit With Antitrust Suit Over MiraLax

Law360, New York (March 13, 2007, 12:00 AM EDT) -- A New York drug cooperative has filed a proposed class action against Braintree Laboratories Inc., accusing the drug maker of conspiring to block rivals from marketing a generic version of its laxative MiraLax and improperly listing a patent with the U.S. Patent and Trademark Office.

The lawsuit, filed Monday by Rochester Drug Co-Operative Inc. in the U.S. District Court for the District of Delaware, alleges that Braintree’s anti-competitive scheme allowed it to charge supracompetitive prices for MiraLax, or polyethylene glycol 3350, an osmotic laxative that causes...
To view the full article, register now.